Spur's Gene Therapy Nears Milestone with Long-Term Gaucher Disease Data

LONDON – April 21, 2026 – In a move that could mark a turning point for patients with Gaucher disease, Spur Therapeutics announced today it will present new, two-year follow-up data from clinical trials of its investigational gene therapy, avigbagene parvec (FLT201). The results, a key indicator of long-term efficacy and safety, are scheduled for presentation at the prestigious International Working Group on Gaucher Disease (IWGGD) 2026 Symposium in Trieste, Italy, from May 3-6.

The announcement has generated significant anticipation within the medical and patient communities, as the data could bolster the case for FLT201 as a durable, single-administration treatment, potentially liberating patients from the lifelong burden of current therapies.

The Lifelong Burden of Gaucher Disease

Gaucher disease is a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase (GCase). This deficiency leads to the harmful accumulation of fatty substances in the spleen, liver, lungs, and bone marrow. The most common form, type 1, affects an estimated 1 in 40,000 people and is characterized by debilitating symptoms including enlarged organs, anemia, low platelet counts, and severe bone disease.

For decades, the standard of care has been enzyme replacement therapy (ERT), which involves intravenous infusions of a manufactured GCase enzyme, typically every two weeks. While effective for many, ERT is a relentless, lifelong commitment. An alternative, substrate reduction therapy (SRT), involves daily oral medication but is not suitable for all patients and comes with its own set of limitations.

"The current treatments, while life-saving, define a patient's schedule and lifestyle," noted a clinical expert in rare diseases who is familiar with the condition. "The need for constant infusions or daily pills is a significant physical and psychological burden. The entire field is looking for a solution that offers not just management, but long-term freedom from the disease's grip."

This is the critical unmet need Spur Therapeutics aims to address. A successful one-time gene therapy could fundamentally reshape the treatment paradigm, shifting the goal from chronic management to a sustained, long-term solution.

A Potential One-Time Fix: The Promise of FLT201

FLT201 is an investigational gene therapy designed to deliver a functional copy of the GBA1 gene—the gene responsible for producing the GCase enzyme—directly to the liver using a proprietary adeno-associated virus (AAV) vector. The therapy delivers a codon-optimized gene that produces GCase85, an engineered version of the enzyme designed for enhanced stability and uptake by target cells.

The goal is to enable the patient's own body to continuously produce the necessary enzyme, effectively correcting the underlying genetic defect with a single intravenous infusion.

Previous data from the Phase 1/2 GALILEO-1 and GALILEO-2 trials have been highly encouraging. Results presented in early 2025 showed that a single dose of FLT201 led to rapid and sustained reductions in key disease biomarkers. Critically, all trial participants were able to stop their prior ERT or SRT treatments and have remained off them, while showing improvements in blood counts and organ volumes.

The upcoming oral presentation by Dr. Ida Schwartz will provide the first look at two-year follow-up data, a crucial test of the therapy's durability. Sustained efficacy at the two-year mark would be a major validation of Spur's platform and a significant step toward proving the long-term viability of this approach. Further presentations will detail the therapy's impact on bone health—a major source of morbidity for Gaucher patients—and provide an update on the now-active Phase 3 registrational trial, GALILEO-3.

A Competitive and Evolving Landscape

Spur Therapeutics is not alone in the race to develop a next-generation therapy for Gaucher disease. The field is active, with several companies pursuing advanced treatments. Prevail Therapeutics, a subsidiary of Eli Lilly, is developing its own AAV-based gene therapy, PR001. Meanwhile, other companies have explored different modalities, such as AVROBIO's ex vivo approach, which modifies a patient's own stem cells outside the body.

However, by presenting robust two-year data, Spur is positioning FLT201 as a frontrunner. This long-term evidence is what regulators, clinicians, and investors look for as a sign of a therapy's true potential. The IWGGD symposium, a premier global forum for Gaucher research, provides the ideal stage for such a significant data reveal.

Spur's Strategic Ascent

The company behind this promising candidate, Spur Therapeutics, is itself a product of recent strategic consolidation in the biotech sector. Formed from the 2024 merger of Freeline Therapeutics and SwanBio Therapeutics, the company is backed by the life sciences investment firm Syncona, which holds a 99% stake. This merger, coupled with a fresh infusion of approximately $50 million, has provided Spur with a solid financial footing and an expanded pipeline that now includes a preclinical program for Parkinson's disease, another condition linked to GBA1 gene mutations.

This financial stability is crucial as the company advances FLT201 into its pivotal GALILEO-3 trial. This Phase 3 study, which will enroll approximately 45 adults, is designed to provide the definitive evidence needed to seek regulatory approval from health authorities like the FDA and EMA. The trial's design, which involves discontinuing background ERT/SRT after infusion, directly targets the therapy's ultimate value proposition: to replace lifelong treatments with a single dose.

As the international Gaucher community prepares to gather in Trieste, all eyes will be on Spur's presentation. The data to be unveiled could offer the strongest proof yet that a future free from the relentless cycle of infusions and pills is within reach for thousands of patients living with Gaucher disease.